Free Trial

Marinus Pharmaceuticals Q3 2023 Earnings Report

Marinus Pharmaceuticals logo
$0.54 +0.00 (+0.75%)
As of 01/3/2025 05:45 PM Eastern

Marinus Pharmaceuticals EPS Results

Actual EPS
-$0.61
Consensus EPS
-$0.67
Beat/Miss
Beat by +$0.06
One Year Ago EPS
N/A

Marinus Pharmaceuticals Revenue Results

Actual Revenue
$7.34 million
Expected Revenue
$6.54 million
Beat/Miss
Beat by +$800.00 thousand
YoY Revenue Growth
N/A

Marinus Pharmaceuticals Announcement Details

Quarter
Q3 2023
Time
N/A

Conference Call Resources

Conference Call Audio

Marinus Pharmaceuticals Earnings Headlines

Marinus (MRNS) Gets a Hold from Truist Financial
DeFi Coin on Verge of Breakout!
The blueprint for millionaires is here. Don't let this be the missed opportunity you regret for years.
See More Marinus Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Marinus Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Marinus Pharmaceuticals and other key companies, straight to your email.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals (NASDAQ:MRNS), a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, and tuberous sclerosis complex. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation and Tenacia Biotechnology (Shanghai) Co., Ltd. Marinus Pharmaceuticals, Inc. was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.

View Marinus Pharmaceuticals Profile

More Earnings Resources from MarketBeat